Pershing Square Activist Presentation Deck
Pershing Square is Proposing a Slate of Qualified and
Independent Nominees to Protect Shareholder Interests
Betsy Atkins (61) Chief Executive Officer of Baja LLC
• CEO of Baja LLC, an independent venture capital firm focused on technology, renewable sciences, and sciences, since 1994
• Co-founded several successful high tech and consumer companies, including Ascend Communications, which was sold to
Lucent Technologies in 1999 for $24 billion
•
Formerly CEO and Chairman of Clear Standards, an on-demand enterprise energy management sustainability software
company, from 2008 to 2009, at which time it was acquired by SAP AG. Former Chairman of the Board of Directors of Third
Screen Media, a company that was eventually sold to AOL
• Has served as a director of Polycom, Inc. since April 1999, Schneider Electric, SA since April 2011, HD Supply Holdings, Inc.
since September 2013, and Ciber Inc. since July 2014. Formerly served on the Boards of Directors of Human Genome
Sciences Inc., HealthSouth Corporation, Vonage Holdings Inc., Towers Watson & Co., Reynolds American Inc., SunPower
Corporation, and Chico's FAS, Inc. Has agreed she will remain on only three other boards if elected to Allergan's board
Cathleen P. Black (70) Senior Advisor at RRE Ventures LLC
• Senior Advisor at RRE Ventures LLC, an early stage venture capital firm, since 2011, and has served on the boards of two of
RRE Ventures LLC's portfolio companies, Yieldbot Inc. and Bark & Co Inc. She is also a board member of PubMatic, Inc.
• Previously served as President of Hearst Magazines and also served as a director of the Hearst Corporation from January
1996 until late 2010. Served as President of USA Today from October 1983 until June 1991 and was a board member of the
parent company, Gannett Co.
• Served as a director of Vibrant Media Inc., a global leader of in-content contextual technology, from October 2012 until 2013,
served as an independent director of International Business Machines Corp. from 1995 until 2010, and served as a director
of The Coca-Cola Company from 1992 until 2010
Fredric N. Eshelman (65) Principal of Eshelman Ventures, LLC
• Principal at Eshelman Ventures, LLC, which is a fund that invests primarily in early-stage healthcare
• Served as Founding Chairman of Furiex Pharmaceuticals, Inc., a drug development company, from its founding in 2009 until
the sale of the company to Forest Laboratories LLC in July 2014 for $1.5 billion. Founded Pharmaceutical Product
Development (PPD), an international contract research organization, and served as the CEO of PPD until 1989 and from
July 1990 until July 2009, Vice Chairman of its board of directors from July 1993 until July 2009, and Executive Chairman
from July 2009 until its sale to private equity in 2011 for $3.9 billion. From 1989 until 1990, Dr. Eshelman was Senior Vice
President of Development at Glaxo, Inc. and served on the board of the U.S. subsidiary of Glaxo Holdings plc.
. Currently serves as director on several private company boards. Served on the board of Princeton Pharma Holdings LLC
from February 2008 until May 2010, when it was acquired by Valeant Pharmaceuticals International, Inc.
26View entire presentation